Prognose

Das durchschnittliche Kursziel der Analysten beträgt +1,34€(−91,80%). Der Median liegt bei +1,34€(−91,80%).

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

Earnings Estimates Rising for Rigel (RIGL): Will It Gain?
Rigel (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.» Mehr auf zacks.com
Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet
The mean of analysts' price targets for Rigel (RIGL) points to an 82.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.» Mehr auf zacks.com
Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum
Rigel Pharmaceuticals, Inc. shows strong momentum, with a 68% YoY revenue increase, driven by TAVALISSE, GAVRETO, and REZLIDHIA, suggesting a shift to a durable growth stock. Q1 net income of $11.4M and improved gross margins highlight Rigel's operating leverage, reducing the need for dilutive fundraising and supporting future R&D investments. R289's promising pipeline progress and TAVALISSE's patent extension to 2032 bolster Rigel's long-term outlook, despite reliance on key products and competitive markets.» Mehr auf seekingalpha.com

Im letzten Quartal hatte RIGEL PHARMACEUTICALS INC einen Umsatz von 55,35 Mio€ und ein Nettoeinkommen von 13,78 Mio€